Amprenavir is an HIV-1 protease inhibitor that blocks viral particle maturation by preventing cleavage of Gag-Pol polyprotein precursors, largely superseded clinically by its prodrug fosamprenavir but still relevant for legacy antiretroviral manufacturing. Simson Pharma's Amprenavir reference standard supports continued compendial compliance for these formulations.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Amprenavir Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.
